Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : NVX-COV2373,Matrix-m1
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Novavax
Deal Size : Undisclosed
Deal Type : Agreement
Baxter BioPharma Solutions Announces Sterile Manufacturing Agreement for Novavax COVID-19 Vaccine
Details : Baxter BioPharma Solutions has entered into an agreement to provide sterile manufacturing services for NVX-CoV2373, Novavax’ COVID-19 recombinant nanoparticle vaccine candidate with Matrix-M adjuvant.
Product Name : Nuvaxovid
Product Type : Vaccine
Upfront Cash : Undisclosed
January 21, 2021
Lead Product(s) : NVX-COV2373,Matrix-m1
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Novavax
Deal Size : Undisclosed
Deal Type : Agreement